The effects of zoledronic acid on mandibular fracture healing in an osteoporotic model: A stereological study

Journal of Craniofacial Surgery

Volumn 24, Issue 4, 2013, Pages 1221-1224

  Sener, Ismail ^a   Bereket, Cihan ^a   Kosker, Huseyin ^b   Turer, Akif ^c   Tek, Mustafa ^d   Kaplan, Suleyman ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b CUMHURIYET UNIVERSITY   (Turkey)

^c ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^d ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

Author keywords

mandible fracture; Osteoporosis; ovariectomy; stereology; zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL; BONE DEVELOPMENT; BONE PLATE; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; FRACTURE HEALING; MANDIBLE; MANDIBULAR FRACTURES; OSTEOPOROSIS; OVARIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE PLATES; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FEMALE; FRACTURE HEALING; IMIDAZOLES; MANDIBLE; MANDIBULAR FRACTURES; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84880893514     PISSN: 10492275     EISSN: 15363732     Source Type: Journal    
DOI: 10.1097/SCS.0b013e3182997816     Document Type: Article

References (40)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis: prevention, diagnosis and treatment. JAMA 2001;285:785-795
2. Kroger H, Tuppurainen M, Honkanen R, et al. Bone mineral density and risk factors for osteoporosis population-based study of 1600 perimenopausal women. Calcif Tissue Int 1994;55:1-7
3. Seeman E, Young N, Szmukler G, et al. Risk factors for osteoporosis. Osteoporos Int 1993;3:40-43
4. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am 2005;87:1609-1618
5. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest 2005;115:200-208
6. Ralston SH, Coleman R, Fraser WD, et al. Medical management of hypercalcemia. Calcif Tissue Int 2004;74:1-11
7. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330:769-773
8. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661
9. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15: 1467-1476
10. Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonate induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-473
11. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003;25:2669-2708
12. Gasser JA, Ingold P, Venturiere A, et al. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008;4:544-551
13. Nguyen TV, Sambrook PN, Kelly PJ. Prediction of osteoporotic fractures by postural instability and bone density. Br Med J 1993;307: 1111-1115
14. Gilles JA, Carnes DL, Dallas MR, et al. Oral bone loss is increased in ovariectomized rats. J Endod 1997;23:419-422
15. Loza JC, Carpio LC, Dziak R. Osteoporosis and its relationship to oral bone loss. Curr Opin Periodontol 1996;3:27-33
16. Lasota A, Danowska-Klonowska D. Experimental osteoporosis-different methods of ovariectomy in femalewhite rats. Rocz Akad Med Bialymst 2004;49:129-131
17. Geuens G, Gundersen GG, Nuydens R, et al. Ultrastructural colocalization of tyrosinated and detyrosinated alpha-tubulin in interphase and mitotic cells. J Cell Biol 1986;103:1883-1893
18. Odaci E, Sahin B, Sonmez OF, et al. Rapid estimation of the vertebral body volume: a combination of the Cavalieri principle and computed tomography images. Eur J Radiol 2003;48:316-326
19. Saadat P, Rashid I, Latiffah AL. Incision choice in laparotomy: a comparison of two incision techniques in ovariectomy of rats. World Appl Sci J 2008;4:537-540
20. Turner RT, Maran A, Lotinun S, et al. Animal models for osteoporosis. Rev Endocr Metab Disord 2001;2:117-127
21. McCann RM, Colleary G, Geddis C, et al. Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 2008;26:384-393
22. Gao Y, Luo E, Hu J, et al. Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats. Bone 2009;44:225-232
23. Gao Y, Zou S, Liu X, et al. The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials 2009;30:1790-1796
24. Einhorn TA. The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998;355:7-21
25. Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-144
26. Hughes DE, MacDonald BR, Russell RG, et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-1935
27. Komatsubara S, et al. Human parathyroid hormone (1Y34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 2005;36:678-687
28. Bi LX, Mainous EG, ZengY, et al. Osteoformin accelerates fresh fracture healing in rats. J Oral Maxillofac Surg 2007;65:2470-2474
29. Conflitti J, Graves M, Russell G, et al. Plating of rat femoral shaft osteotomies: report of a technique and preliminary results. Biomed Sci Instrum 2003;39:278-283
30. Wingerter S, Calvert G, Tucci M, et al. Comparison of two different fixation techniques for a segmental defect in a rat femur model. J Invest Surg 2007;20:149-155
31. Bilston LE, Little DG, Smith NC, et al. Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech (Bristol, Avon) 2002;17:716-718
32. Astrand J, Harding AK, Aspenberg P, et al. Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats. BMC Musculoskelet Disord 2006;7:1-7
33. Gasser JA, Green JR, Shen V, et al. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone 2006;39:787-795
34. Doi Y, Miyazaki M, Yoshiiwa T, et al. Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model. Bone 2011;49:777-782
35. Ottewell PD, Mönkkönen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-1178
36. Kumar D, Kumar V, Little DG, et al. Evaluation of biodistribution by local versus systemic administration of 99mTc-labeled pamidronate. J Orthop Sci 2006;11:512-520
37. Amanat N, McDonald M, Godfrey C, et al. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res 2007;22:867-876
38. Smith EJ, McEvoy A, Little DG, et al. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J Bone Miner Res 2004;19:1698-1705
39. Novaes RD, Penitente AR, Talvani A, et al. Use of fluorescence in a modified dissector method to estimate the number ofmyocytes in cardiac tissue. Arq Bras Cardiol 2012;98:252-258
40. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984;134:127-136